论文部分内容阅读
CDB-2914是新的具抗孕激素和抗皮质激素活性的物质,结构与孕酮和米非司酮相似。Ⅰ期安全性和毒性研究显示1～200 mg无抗糖皮质激素副反应,半衰期12～136 h。本文研究其在卵泡中期的作用特征,单剂量10～100 mg对卵泡生长、排卵及黄体期内膜成熟作用。 44例正常月经周期健康妇女,连续观察3周期。第1、3周期为治疗前后,确认周期长度及排卵,第2周期为治疗周期。如第1周期有排卵(卵泡发育正常,周期长度正常,黄体中期孕酮>4 ng/ml),第2周期6～8 d起超声测卵泡,计卵泡数并测量直径>10 mm者,所有与最大卵泡相差2 mm内的卵泡均为主
CDB-2914 is a new antiprogestin and anti-corticosteroid substance with a similar structure to progesterone and mifepristone. Phase I safety and toxicity studies have shown that 1 ~ 200 mg anti-glucocorticoid side effects, half-life of 12 ~ 136 h. This article studies its role in follicular metaphase, a single dose of 10 ~ 100 mg on follicular growth, ovulation and luteal phase of endometrial maturation. Forty-four healthy women with normal menstrual cycle were observed for 3 cycles. The first and third cycles before and after treatment to confirm the length of the cycle and ovulation, the second cycle for the treatment cycle. Such as ovulation in the first cycle (normal follicle development, normal cycle length, mid-luteal progesterone> 4 ng / ml), the second cycle from 6 to 8 d ultrasound measured follicles, count the number of follicles and measured diameter> 10 mm, all Follicles with the largest follicles within 2 mm are the main